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Gene products of the major histocompatibility complex (MHC) 1 display a complex 
pattern  of serologically  defined  antigenic  determinants  (1,  2).  Attempts  to  resolve 
these antigenic complexities with conventional alloantisera have been complicated by 
the fact that these sera represent heterogeneous populations of antibody specificities. 
Often, such sera must be rendered functionally monospecific by selective absorption, 
and they frequently may display low cytotoxicity titers. In addition to these problems, 
for human studies, the preparation of anti-HL-A sera by conventional immunization 
procedures is not permitted for ethical reasons. Monoclonal antibodies derived from 
hybridoma  cell  lines  offer  an  important  alternative  to  conventional  alloantisera 
because they represent homogeneous antibody populations that can be prepared with 
specificity for a wide variety of determinants (3, 4), which include antibodies reactive 
with MHC determinants. 
For reasons that remain unclear, it is difficult at present to obtain large numbers of 
different hybridomas that secrete anti-H-2 antibodies by fusing lymphoid cells from 
alloimmunized mice to any of the mutant murine myelomas. A collection of anti-H- 
2  monoclonal  antibodies  was  recently described,  the  production  of which  required 
several years' effort  (5-7).  This comparatively rare occurrence of anti-MHC  hybri- 
domas,  however, does  not  appear to be a  general case.  In this communication,  we 
describe our experience with the production of large numbers of anti-rat MHC (Rt-1 
and Ag-B) hybridomas derived from interspecies fusion of alloimmune rat spleen cells 
with  several  mutant  mouse  myelomas. Antibodies  from the  supernates  of 24  such 
cloned  hybridoma cell  lines  were tested  for their reactivity against  rat  MHC  gene 
products with appropriate congenic rat strains. They were also tested for their cross- 
reactivity  on  target  cells  from  various  rats,  mice,  and  humans.  By  analyzing  the 
reactivity patterns of these monoclonal antibodies it is possible to derive some initial 
estimates of the degree of heterogeneity of anti-MHC antibodies. 
* Supported by National Cancer Institute grant CA-15822 and contract CB-74149. 
1  Abbreviations used in this paper: BN, Brown Norway; Con A, concanavalin A;  HAT, hypoxanthine, 
amniopterin, and thymidine; L, Lewis; MHC, major histocompatibility complex; Vn, variable region of 
the immunoglobulin heavy chain; VL, variable region of immunoglobulin light chain. 
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Materials and Methods 
Animals 
RAT STgAINS.  The rat strains used in this study are indicated in Table I along with their 
MHC haplotypes and sources. 
MOUSE STRAINS.  All  mice were  purchased  from  The Jackson  Laboratory,  Bar  Harbor, 
Maine with  the  following exceptions:  B10.S  mice were  obtained from  Dr.  D.  G6tze  (Max 
Planck-Institut ffir Biologic, Tiibingen, Federal Republic of Germany), D2.GD mice from Dr. 
F.  Lilly (Albert Einstein Medical School,  New York),  and A.TL mice from Dr.  P.  Doherty 
(Wistar Institute, Philadelphia, Pa.). 
Production and Maintenance of Hybridomas.  Table II shows  the derivation of the hybridomas 
used in these studies, some of.which have been described previously (8, 9). This communication 
will deal with the first  24 cloned hybridomas, which were derived from 6  different fusions 
involving alloimmune spleen cells from 5 different Lewis  (L) rat donors and 3 HAT-sensitive 
mutant myeloma cell lines.  Many additional positive hybridomas were also derived in these 
fusions; these have been placed into frozen storage and will be examined later. 
Techniques for the  immunization of spleen cell donors, cell  fusion, hybridoma selection, 
maintenance, and cloning have all been described in detail elsewhere  (8, 9).  In brief, spleen 
cells from adult L rats immunized one to three times with spleen and lymph node cells from 
(L/Brown Norway  [BN])Fx donors were  fused  to  mutant myeloma cells  with  polyethylene 
glycol and seeded into microtiter dishes in selective hypoxanthine, amniopterin, and thymidine 
(HAT) medium (10). Supernates from wells that contained macroscopic colonies were assayed 
in the complement-mediated cytotoxicity assay,  and cells from positive wells were expanded, 
cloned in semisoft agarose (11), and/or frozen to await further studies. Criteria for cloning have 
been published (9) and antibodies from cloned lines were used in all subsequent assays reported 
in this study. 
To obtain fluids that contained high concentrations of the hybridoma antibody, D4.69A, 
hybridoma cells  were  grown  in  immunosuppressed animals as  subcutaneous tumors.  This 
required profound immunosuppression; for example, BALB/c mice were treated with 40/~1 of 
anti-thymocyte  serum (Microbiological Associates, Inc., Walkersville, Md.) intraperitoneally  on 
2 consecutive d. 3 d later, the animals were irradiated (600 rad), reconstituted with 10-20 ×  106 
anti-Thy  1.2-treated  BALB/c  bone  marrow  cells  given  intravenously, and  10-20  ×  l0  s 
hybridoma cells were inoculated subcutaneously between the scapulae. Tumors were palpable 
after ~2 wk, at which time sera and/or thoracic duct lymph were obtained. 
Serological Assays 
COMPLEMENT-MEDIATED CYTOTOXICITY.  This assay,  used  both  for  initial identification of 
positive hybridomas and for characterization of their specificities,  has been described in detail 
elsewhere  (9). The complement sources were selected  lots of rabbit serum (diluted 1:8 to 1:12) 
that were chosen by screening samples from many individual young rabbits; they required 
absorption with Noble agar (Difco Laboratories, Detroit, Mich.) and rat spleen cells before use. 
Supernates from the mutant myelomas were used as background controls. Maximum lysis 
was obtained with a hybridoma antibody known to lyse 100% of the relevant targets as verified 
with trypan blue. The positive control for L  target cells was supernate from the hybridoma 
I1.69.1,  which is specific for L and BUF target cells and was a gift from Dr. Donald Bellgrau 
(University of Pennsylvania  School  51  of Medicine, Philadelphia, Pa.). In those cases where  Cr- 
release  was intermediate between the  positive and negative control values, the results were 
verified with a trypan blue dye exclusion assay. 
MICROLYMPHOCYTOTOXIClTY ASSAY.  The procedure of Zmijewski (12) was used to test  the 
specificities of the hybridoma antibodies on human cells. 
HEMAGGLUTINATION  ASSAY.  A modification of the method of Severson and Thompson (13) 
was used. An enhancing antibody (goat anti-rat Ig) was included in all assays; its presence was 
necessary to observe hemagglutination with IgG hybridoma antibodies. 
Ammonium Sulfate Precipitation.  Certain hybridoma culture supernates (Table V) were con- 
centrated by precipitation with an equal volume of saturated ammonium sulfate. Precipitates 
were reconstituted to one-tenth the original volume and generally had antibody titers that were 
10 times higher than the original supernates. 
Isotype Characterization.  The heavy-chain isotypes  of the y2b- and y2c-hybridoma antibodies SMILEK ET  AL. 
TABLE  I 
Rat Strains Used in This Study 
Strain  Designation  Re-1  (Ag-B)  Source* 
Lewis  L  1  ( 1  )  M 
Wistar Furth  WF  u  (2)  M 
Brown Norway  BN  n  (3)  M +  A 
DA  DA  a  (4)  A 
August 28807  AUG  c  (5)  A 
Buffalo  BUF  b  (6)  M 
L.B3  n  (3)  A 
BN.B1  1  (1)  A 
* (M)  Microbiological Associates,  Inc.  (A)  Animal Colonies,  University of 
Pennsylvania and The Wistar Institute, Philadelphia, Pa. 
TABLE  II 
Summary of Rat  X  Mouse Fusions 
1141 
Fusion se- 
ries 
Fusion partners 
Spleen  Myeloma (source) 
Number of  Number of  Number of  Number of 
wells positive  clones re-  wells positive  wells positive  for anti-BN 
for growth  for anti-BN  MHC  ported in 
(total)  (total tested)  (total tested)  this study 
D4 
K2 
N2 
R6 
R9 
RI0 
L1  P3/X63-Ag8*  189 (288)  15 (140)  3 (3)  3 
L2  SP2/0-AgI4:[:  19 (288)  11 (19)  5 (5)  3 
L3  P3/X63-Ag8  205 (281)  42 (205)  19 (19)  8 
L4  P3/X63-AgS.653§  93 (288)  10 (93)  8 (8)  1 
L5  SP2/0-AgI4  169 (288)  50 (169)  37 (38)  8 
L5  P3/X63-AgS.653  112 (288)  27 (112)  21  (21)  1 
* Provided by 
England. 
:~ Provided by 
§ Provided by 
Dr. C. Milstein, Medical Research Council, Laboratory of Molecular Biology, Cambridge, 
Dr. G. K6hler, Basel Institute of Immunology, Basel, Switzerland. 
Dr. J. Kearney, University of Alabama Medical School, Birmingham, Ala. 
were determined  in Ouchterlony analysis with antisera  generously provided by Dr.  H. Bazin 
(University of Louvain, Brussels, Belgium). Hybridoma D4.37.25.24 was typed as "p" with this 
same method.  All other hybridoma  antibodies  were subsequently  typed  for the #-isotype by 
their ability to inhibit the binding of x~I-labeled rabbit  anti-mouse-#  to D4.37.25.24,  with  a 
modification of the method of Press and Klinman (14).  125I-labeled  anti-# was kindly provided 
by Dr. M. Cancro (University of Pennsylvania School of Medicine). 
Results 
Frequency ofAnti-MHC Hybridoma Antibodies.  Table II shows that a large proportion 
of microtiter wells seeded after fusion displayed growth of proliferating hybrids. When 
supernates from these cultures were tested for cytotoxicity on concanavalin A (Con A) 
blast cells derived from BN lymph node cells, 11-58% of them were positive. Moreover, 
of the 94 hybridomas tested that were positive on BN target cells, 93 were positive on 
cells from the MHC congenic strain L.B3. 
Table III describes the first 24 clones derived from this series of 6 fusions in terms 
of heavy-chain isotypes and antibody activities as culture supernates in cytotoxieity 
and  hemagglutination  assays.  Several  points  emerge:  (a)  Most  (21  of 24)  of the 
monoclonal antibodies are IgM.  (b)  All of them are cytotoxic on Con A  blasts from 
BN and L.B3  rats, but  have no activity against  cells of the reciprocal congenic rat 1142  RAT ANTI-MAJOR HISTOCOMPATIBILITY COMPLEX  ANTIBODIES 
TABLE  III 
Heavy-Chain Isotypes, Cytotoxicity,  and Hemagglutination Titers of Monoclonal 
Antibodies  from Culture Supernates 
Hybridoma 
Heavy-  Reciprocal cytotoxicity titers  Reciprocal 
chain iso-  HA titer on 
type  BN  L.B3  BN.B 1  BN erythro- 
cytes 
D4.37.25.24  #  6,200  4,700  0  4,094 
D4.68.3.22  y2b  66  56  0  16 
D4.69A*  y~c  530  240  0  125 
K2.3.17  /~  870,000  240,000  0  8,192 
K2.7.2  /~  220,000  660,000  0  4,096 
K2.13.2  ~  8,200  1,400  0  1,024 
N2.9.2  #  510  220  0  0 
N2.11.6  #  1,350  890  0  32 
N2.25.8  /~  590  290  0  16 
N2.27.30  /~  625  860  0  16 
N2.34.1  /~  590  290  0  0 
N2.36.2  #  390  220  0  0 
N2.54.3  /~  110  74  0  16 
N2.78.1  #  590  190  0  64 
R6.20.2  #  29,000  5,400  0  256 
R9.9.12  #  5,060  1,640  0  128 
R9.13.1  #  1,400  2,660  0  1,024 
R9.17.12  #  48  48  0  64 
R9.21.4  #  1,350  1,000  0  32 
R9.31.10  #  340  130  0  8 
R9.36.4  /~  590  510  0  256 
R9.61.8  /~  1,400  2,260  0  512 
R9.75.9  )'2c  330  625  0  1,024 
R10.14.2  #  1,350  890  0  1,024 
* Titers performed with lymph from tumor-bearing animal. 
strain BN.B 1, a  finding that establishes the anti-MHC  specificity of these monoclonal 
antibodies.  In addition,  all of the IgM hybridoma  antibodies lyse >90% unstimulated 
BN  lymph  node  cells  (data  not  shown),  thereby  establishing  that  the  determinants 
detected  are expressed  on both  B  and  T  cells.  (c)  Most  (21  of 24)  of these antibodies 
also  agglutinated  BN  erythrocytes  that  display  class  I  MHC  determinants  but  lack 
class II determinants. 
Cross-Reactivities of Hybridoma Antibodies on  Target Cells from  AUogeneic Rat Strains and 
from  Different Mouse Strains.  The  cross-reactivity  patterns  of these  monoclonal  anti- 
bodies were tested on a  panel  of Con A  blast  cells from six different rat  strains,  each 
expressing  a  different  MHC  haplotype  (Table  IV),  and  from  eight  different  mouse 
strains,  expressing  five different  H-2  haplotypes  (Table  V).  Hybridoma  antibodies 
were used as undiluted culture supernates  except where indicated.  All of them caused 
complete lysis of BN target cells and showed no activity on L  target cells. When  tested 
on  third-party  targets  of either  rat  or  mouse  origin,  lysis  was  either  complete  or 
negligible, with few exceptions. 
The  extent  of cross-reactivity  of these  monoclonal  antibodies  on  different  mouse 
strains  was  surprisingly  high.  11  of the 24 antibodies  showed no reactivity;  2, on  the 
other  hand,  were  lytic  for  every  murine  target  tested.  Further  testing  of these  two SMILEK  ET  AL. 
TABLE  IV 
Cytotoxidty Patterns of Monodonal Antibody Supernates on 
Strains* 
Target Cells from Six Rat 
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BN  L  WF  DA  August  Buffalo 
Hybridoma  Rt-l"  Rt-11  Rt-I u  Rt-l"  Rt-1 e  Rt-I b 
D4.37.25.24  100  0  77  100  0  100 
D4.68.3.22  99  -  1  3  -  1  39  0 
D4.69A:~  93  1  7  1  93  0 
K2.3.17  97  --1  3  -3  1  --1 
K2.7.2  91  -2  2  -2  0  --1 
K2.13.2  88  -  1  1  69  86  1 
N2.9.2  105  0  4  -l  !  0 
N2.11.6  100  0  8  -2  0  0 
N2.25.8  92  0  -  1  -  1  1  -2 
N2.27.30  91  -3  6  -3  1  -2 
N2.34.1  10l  -2  4  0  3  0 
N2.36.2  101  --1  0  0  -1  -1 
N2.54.3  100  -  1  4  -2  1  -  1 
N2.78.1  95  -  1  0  1  0  -  1 
R6.20.2  96  -  1  1  44  100  -  1 
R9.9.12  100  0  1  0  80  -  1 
R9.13.1  102  0  3  2  6  -1 
R9.17.12  113  0  2  1  1  0 
R9.21.4  113  -1  3  2  82  --1 
R9.31.10  112  -1  2  1  74  0 
R9.36.4  116  -  1  1  -  l  93  0 
R9.61.8  114  -1  3  -1  2  0 
R9.75.9  104  -  1  2  0  60  0 
R10.14.2  115  0  3  -1  2  0 
I1.69.1  -3  81  0  -4  7  90 
* Data are presented as the percent cytotoxicity calculated in the 51Cr-release assay. 
With thoracic duct lymph from tumor-bearing animal. 
antibodies  (D4.37.25.24  and  N2.25.8)  on  a  widely  expanded  panel  of mouse  target 
cells,  including  cells  from  wild  mice,  and  several  H-2  mutant  mice,  has  without 
exception  shown  lysis of each  mouse  target  (T.  McKearn  and  D.  Shreffler.  Unpub- 
lished data.). The  remaining  11 antibodies were cytotoxic for cells from certain mouse 
strains, and  it is apparent  that  those antibodies  that were cytotoxic  for target cells of 
any mouse strain were always positive for BALB/c  target cells. 
Anti-Rat  MHC  Monoclonal  Antibodies  Also  Detect  Mouse  H-2  Antigens.  11  of the  24 
monoelonal  anti-rat  MHC  antibodies  tested  on  the panel  of mouse  targets  detected 
polymorphic  determinants  in  this species;  i.e.,  they  recognized  determinants  present 
in  some  murine  strains  that  were  absent  in  others.  Target  cells  from  H-2  congenic 
mouse strains were therefore used to determine  if the polymorphic  determinants  might 
be linked to the H-2  locus  (Table V). 
All of the antibodies  that  were positive on BALB/c  and  DBA/2  (H-2  d)  target cells 
and  negative  on  C57BL/10  (H-2°),  were  also  positive  on  B10.D2  target  cells,  a 
congenic strain with  the C57BL/10  background  and  the H-2  d haplotype  of DBA/2. 
Similarly, other antibodies  lysed C57BL/10  (H-2  b)  but  failed to lyse SJL  (H-Z)  and 
the congenic strain B10.S  (H-2"). 
Table  VI shows the results from studies with cells from intra-H-2  recombinant  mice 1 144  RAT  ANTI-MAJOR  HISTOCOMPATIBILITY  COMPLEX  ANTIBODIES 
TABLE  V 
Cytotoxicity Patterns of Monoclonal Antibody Supernates on Murine Target Cells* 
Hybridoma  BALB/c  DBA/2  BI0.D2  CBA  C57BL/10  BI0.S  SJL  DBA/I 
H-2  d  H.2  d  H_2  d  H_2  k  H_2  h  H-2  ~  H_2  ~  H.2  q 
D4.37.25.24  100  100  100  100  100  100  100  100 
D4.68.3.22  -  10  -  1  0  0  -6  0  -  1  -2 
D4.69A  -8  1  -  1  8  -5  0  13  0 
K2.3.17  98  104  106  100  -7  -2  -2  1 
K2.7.2  91  87  70  100  -9  0  -3  --5 
K2.13.2  -11  ND§  ND  -4  -10  ND  --3  -6 
N2.9.2  0  4  0  10  -8  -2  -7  0 
N2.11.6  92  107  99  5  -7  6  -  1  0 
N2.25.8  94  105  108  100  97  106  100  99 
N2.27.30  86  10l  100  1  -4  0  -4  -5 
N2.34.1  -  11  ND  ND  l  -9  ND  --2  0 
N2.36.2  -13  ND  ND  2  -9  ND  -3  -7 
N2.54.3  90  107  96  3  -9  -3  -2  -6 
N2.78.1  90~:  105  96  103~:  -9:]:  -2  --1~:  0~: 
R6.20.2  97  105:~  105  101  91~  6~z  -1  2 
R9.9.12  -10  ND  ND  1  -I0  ND  -3  -6 
R9.13.1  91  102:]:  107  88  95:]:  2~:  11  14 
R9.17.12  95  95~:  97  107  88t:  -1~  -1  1 
R9.21.4  -  11  ND  ND  3  -8  ND  -  1  2 
R9.31.10  -6  ND  ND  0  -8  ND  -2  1 
R9.36.4  -8  ND  ND  13  -4  ND  1  2 
R9.61.8  96  95:~  88  94  98~  4:~  0  6 
R9.75.9  -4  ND  ND  8  -6  ND  -2  3 
R i0.14.2  103  107  109  103  90  1  0  2 
* Data  are  presented  as  the  percent  cytotoxicity calculated  in 
antibody D4.37.25.24 serving as the positive control. 
:~ Assay done with ammonium  sulfate precipitate. 
§  Not done. 
the  ~lCr-release  assay,  with  hybridoma 
TABLE  VI 
Cytotoxicity Patterns of Monoclonal Antibody Supernates on Target CeUs  from H-2 Recombinant Mice* 
B10.D2  d  d  d  d  d  d  d  d  d  +  -  +  +  +  + 
D2.GD  d  d  d  b  b  b  b  b  b  +  -  +  +  +  + 
C3H  k  k  k  k  k  k  k  k  k  +  -  +  +  -  - 
A/J  k  k  k  k  k  d  d  d  d  +  -  +  +  --  - 
B 10.A(4R)  k  k  b  b  b  b  b  b  b  +  -  +  +  -  -- 
B10.A(5R)  b  b  b  k  k  d  d  d  d  +  ..... 
A.TL  s  k  k  k  k  k  k  k  d  +  ..... 
B10.S  s  s  s  s  s  s  s  s  s  +  ..... 
C57BL/10  b  b  b  b  b  b  b  b  b  +  ..... 
.  d  CytotoxicitYktiters on target cells bearing K  alleles varied from 1:1,000 (N2.27.30)  to  1:790,000 (K2.7.2). 
Titers on K  target cells varied from 1:12,000 (K2.3.17) to  1:79,000 (K2.7.2). SMILEK ET  AL.  1145 
TABLE  VII 
Cytotoxicity Patterns of Monoclonal Antibodies on Human Peripheral T Lymphocyte Target Cells* 
Human lymphocyte donor number  Hybrid- 
oma  47(5):1:  158(1)  239(25)  259(11)  282(3)  308(2)  319(1) 
D4.37.25.24  ++++  ++++  ++++  ++++  ++++  ++++  ++++ 
K2.3.17  ++++  ++++  -  ++++  ++++  ++++  ++++ 
K2.7.2  ++++  ++++  -  ++++  ++++  ++++  ++++ 
N2.11.6  -  +++  ....  ++ 
N2.25.8  ++++  ++++  ++++  ++++  ++++  ++++  ++++ 
N2.27.30  --  ++  ..... 
R6.20.2  -  +++  --  ++++  -  -  +++ 
R9.13.1  -  ++++  --  ++++  -  ++  +++ 
R9.17.12  -  +++  -  ++++  -  -  ++ 
R9.61.8  -  ++++  -  ++++  -  ++  +++ 
R10.14.2  -  ++++  -  ++++  ++  +++  ++++ 
* ++++, 80-100% cell lysis; +++, 60-79% cell lysis; ++, 40-59% cell lysis; +, 20-39% cell lysis; -, 0-19% 
cell lysis. 
:1: The numbers in parentheses  represent  the number of individuals from the original panel of 48 donors 
who displayed this pattern of lysis. 
used as targets  in an attempt  to localize more precisely the H-2-1inked  determinants 
detected by these monoclonal antibodies.  Hybridoma  antibodies K2.3.17  and  K2.7.2, 
which  are positive on  both  H-2  d and  H-2  k target  cells,  detect  determinants  that  are 
encoded  to  the  left  of I-A  k and  to  the  left  of I-J  d.  Similarly,  hybridoma  antibodies 
N2.11.6  and  N2.27.30,  which lyse H-2  d target  cells, also detect  determinants  that  are 
encoded to the left ofI-J  d. When  positive, these 4 antibodies lyse >90% ofunstimulated 
murine lymph  node target cells. 
Cross-Reactivities  of Anti-Rat  MHC Monoclonal  Antibodies on Human  Cells.  Peripheral 
blood T  lymphocytes  from a  panel  of 48  healthy  unrelated  human  individuals  were 
tested in the microlymphocytotoxicity assay for their sensitivity to lysis by the L  anti- 
BN  hybridoma  antibodies.  Table  VII  shows  that  the  lysis  seen  on  this  panel  of 48 
individuals could be reduced to 7 prototype patterns.  As noted previously with mouse 
target cells, certain antibodies fail to lyse any human  target cells and so, for simplicity, 
have  been  omitted  from  Table  VII.  The  same  two  antibodies  (D4.37.25.24  and 
N2.25.8)  that  lysed every mouse target  cell also lysed every human  target  cell tested. 
A  more extensive analysis  of these  2  antibodies  on  >100  consecutive human  donors 
has  invariably  shown  lysis  (data  not  shown).  The  remaining  nine  antibodies  lysed 
only targets  from certain  individuals,  which  implies detection  of polymorphic  deter- 
minants  in  humans.  Further  investigations  of the  genetic  linkage  and  biochemical 
nature of these polymorphic  human  determinants  are in progress. 
Discussion 
This report describes the derivation and serologic characterization  of 24 cloned rat- 
mouse hybridoma  cell lines. These cell lines were all derived by fusion of spleen cells 
from  alloimmunized  L  rats  with  mutant  mouse  myeloma  cell  lines  and  secrete 
cytotoxic antibodies specific for the products of the Rt-1 n (Ag-B3) MHC  haplotype of 
the  BN  rat.  Several  comments  and  conclusions  can  be  offered  concerning  these 
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First, the fusion of alloimmune rat spleen cells to mutant mouse myelomas resulted 
in the production of many (155 of 738)  hybridomas that secreted antibody specific for 
cell-surface antigens of the BN strain  (Table II). Of the hybridoma antibodies  that 
were tested, most (93 of 94) were shown to be positive on target cells of the congenic 
L.B3 strain (Table II), a finding that establishes their specificity for MHC alloantigens 
of the  Rt-1 n haplotype. The reasons  for the apparent  immunodominance  of MHC 
alloantigens  in  this  situation  is  not  clear, but  this  finding  may reflect  the  frequent 
predominance  of anti-MHC  antibodies  in  alloimmune  sera.  This  approach  to  the 
preparation  of anti-MHC  hybridomas,  therefore,  stands  in  marked contrast  to  the 
experience  of other  groups  with  anti-H-2  hybridomas,  where  the  number  of anti- 
MHC  hybridomas is quite  low  (5-7).  The high yield of rat anti-MHC  hybridomas 
may reflect the use of interspecies somatic cell hybrids or a  heightened  alloimmune 
response of rats compared with mice. The extensive cross-reactivities of the monoclonal 
anti-rat  MHC  antibodies  on  H-2 gene products  (Table V)  seemingly rules out  the 
possibility that these mutant mouse myeloma Cells are not permissive to the secretion 
of anti-H-2 antibodies. 
Second,  the  patterns  of reactivity  on  BN  rat  cells  of the  24  cloned  hybridoma 
antibodies suggest detection of class I gene products of the rat MHC locus  (15);  i.e., 
all of the IgG hybridomas and 18 of the 21 IgM antibodies displayed hemagglutinating 
activity for BN erythrocytes (Table III), and all of the IgM antibodies lysed >90% of 
unstimulated  BN  lymph  node  cells.  Additional  data  derived  from  cross-reactivity 
studies on mouse and human cells suggest recognition of class I MHC determinants 
in those species:  (a) those  11  antibodies that detect polymorphic determinants in the 
mouse  were  shown  with  congenic  strains  to  detect  H-2  gene  products;  (b)  from 
mapping studies with H-2 recombinant  mouse strains,  two of these antibodies were 
shown to detect gene products of the H-2K region. Two additional antibodies detect 
gene products that map to the left of I-J  d and are expressed on >90% of H-2  a target 
cells (Table VI); and (c) several of the monoclonal antibodies lysed >90% of lymphoid 
cells from certain members of a panel of human donors (Table VII), but were negative 
on Daudi cells (data not shown), a  human B lymphoblastoid cell line that does not 
express HLA-A, -B, or -C gene products and fl2-microglobulin  (16).  None of the 24 
antibodies appears to detect class II rat MHC determinants,  the homologues of the 
mouse I region. Because the expression of class II MHC antigens on rat Con A blasts 
may not parallel expression of I-region antigens on mouse Con A blast cells, failure to 
detect class II determinants could be the result of the screening tactics used, but could 
also reflect the relatively simple immunization protocols used for the alloimmunized 
spleen cell donors. 
Third, all of the monoclonal antibodies detected polymorphisms of the rat MHC, 
but they could be further subdivided on the basis of their cross-reactivities on target 
cells from various mouse strains and human donors (Tables V  and VII). It should be 
noted  that  the  patterns  of cross-reactivity were  usually  all  or none.  Three  general 
patterns  of  cross-reactivity  were  noted:  (a)  11  of  the  24  monoclonal  antibodies 
recognize determinants  unique  (thus  far)  to rat  MHC  haplotypes.  The majority of 
these (8 of 11)  detect determinants also present in the August  28807 rat, a crossreac- 
tivity that has been previously described with serum alloantibodies  (17);  (b)  2 of the 
24  antibodies  detect  determinants  on all normal mouse and  human  lymphoid cells 
tested to date. Although these antibodies detect class I MHC polymorphisms in rats, 
the nonpolymorphic expression of those determinants recognized in mouse and human SMILEK ET AL.  1147 
precludes their assignment by classical genetic analysis. These observations, however, 
raise the intriguing possibility that some MHC determinants may be polymorphic in 
one  species  and  highly  conserved  or  nonpolymorphic  in  another  species;  (c)  11 
antibodies detect polymorphisms in the murine MHC, one unique to H-2  d, a second 
shared by H-2  k and H-2  d, and a third polymorphism shared by H-2  d, H-2  k, and H-2  b. 
Nine of these monoclonal antibodies also detect polymorphic determinants in human 
cells.  These antibodies  all  recognize murine  MHC  gene  products  (Table V),  and 
family studies  in  humans  strongly suggest  linkage to the  HL-A gene complex  (H. 
Boyd, D.  Smilek, C.  Zmijewski,  R.  Spielman, and T. J.  McKearn.  Monoclonal rat 
anti-MHC  antibodies detect polymorphisims in humans which are linked to HL-A. 
Manuscript submitted for publication.). 
It is of some interest that those monoclonal antibodies that react with human or 
mouse cells always react with H-2  d, the haplotype of the mutant mouse myeloma cell 
lines used for fusion. We do not currently know whether this is simply a result of the 
particular rat strain combinations used for alloimmunization or of some preferential 
selection of those cells that secrete antibodies cross-reactive with H-2  d gene products. 
Taken  as  a  whole,  these  findings  indicate  an  extensive  sharing  of class  I  MHC 
determinants  in  rats,  mice, and  humans,  and  therefore, certain of these antibodies 
may become useful reagents for both biochemical and genetic studies of MHC gene 
products in a variety of species. 
Fourth, although the number of monoclonal antibodies described in this paper is 
somewhat limited, it is possible to derive some assessment of the heterogeneity of anti- 
MHC  antibodies from the assembly of cross-reactivity patterns  against  rat, mouse, 
and human target cells observed with these hybridoma antibodies (Fig.  1) by using 
the strategy of reactivity pattern analysis. In such an analysis (18)  one assumes that 
differences  in  the  reactivity  patterns  between  two  monoclonal  antibodies  imply 
differences in fine specificities of those antibodies. Similarities in reactivity patterns, 
on  the other hand,  do not  establish  the  two antibodies  to be identical.  Therefore, 
reactivity pattern analysis can provide a  minimal estimate of the degree of antibody 
diversity in a collection of monoclonal antibodies. Two important points emerge from 
such a consideration:  (a) a considerable number of different antibodies comprise the 
anti-MHC response (14 reactivity patterns among 24 hybridomas), and  (b) when a 
given reactivity pattern recurs, it tends to do so within the individual (e.g., reactivity 
patterns 3, 5, and  12) rather than between individuals (e.g., reactivity pattern 2). 
These data suggest  that  considerable heterogeneity exists within  the B  cell anti- 
MHC  repertoire and  imply that  either the germ-line encodes for many anti-MHC 
specificities (19)  or that some of this diversity is generated by somatic mechanisms. 
Reactivity pattern analysis measures the overall diversity that results from combina- 
tional assembly of the variable region of the immunoglobulin heavy chain (VH) and 
the variable region of the immunoglobulin light chain (VL) chains, and, therefore, the 
observed heterogeneity could reside in either VH or VL. Hence, it is possible that these 
antibodies represent a  highly diverse set of VL chains assembled with relatively few 
Vr~ chains, a situation that would reconcile these data to observations showing shared 
VH idiotypes on T  and B cells (20, 21). In addition, because the anti-MHC repertoire 
probably includes  antibodies  that  recognize several  distinct  alloantigenic determi- 
nants, the heterogeneity seen in this collection of anti-MHC  hybridomas is perhaps 
not entirely surprising. 
The issue of recurring reactivity patterns within and between individuals deserves 1148  RAT  ANTI-MAJOR  HISTOCOMPATIBILITY  COMPLEX  ANTIBODIES 
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Fro.  L  Summary of the reactivity patterns of hybridoma antibodies, derived from 5 different L 
rats, on rat, mouse, and human target cells. Rat and mouse data are organized according to Rt-l 
and H-2  haplotypes, respectively.  Human data  is organized as in Table VII.  •  implies positive 
reaction; [] implies negative reaction; and [k implies partial lysis on human target cells. 14 reactivity 
patterns are found with these monoclonal antibodies. 
comment because it is a clear prediction that if true germ-line specificities exist in the 
anti-MHC antibody response, one should be able to demonstrate sharing of at least 
some reactivity patterns between individuals. The only pattern that is shared in this 
initial panel of 24 antibodies is reactivity pattern 2, and we already have preliminary 
evidence that not all members of that  group share idiotypic determinants.  In those 
situations where reactivity patterns are shared among hybridomas derived simulta- 
neously from a single donor, we do not yet know whether such antibodies represent 
true sister clones and whether these represent  (a)  clonal dominance before antigen 
exposure, (b) selective expansion of  certain clones by antigen challenge, (a) preferential 
fusion of certain clones to the mutant  myeloma cells, or  (d)  preferential growth of 
certain clones after fusion. The use of anti-idiotypic antibodies prepared against these 
hybridomas should help resolve some of these basic questions. 
Summary 
24  monoclonal rat  antibodies  are  described that  are  reactive with  determinants 
encoded by the major histocompatibility complex (MHC) of the rat. These hybridoma 
antibodies were derived by fusing mutant mouse myeloma cells to spleen cells from 
Lewis  rats  immunized  with  allogeneic Brown  Norway cells.  All  24  antibodies  are 
cytotoxic for both Brown Norway target cells and  target cells from the appropriate 
MHC congenic rats. Patterns of cytotoxicity and hemagglutination strongly suggest SMILEK ET AL.  1149 
reactivity against class I  (K or D  equivalent)  rat MHC determinants.  Cytotoxic cross- 
reactivity  patterns  were  generated  for each  monoclonal antibody on  a  panel  of rat 
and  mouse lymphoid cells and  human  peripheral  T  lymphocytes. A  high degree of 
interspecies  cross-reactivity was noted with approximately one-half of the antibodies 
positive on human and/or mouse target cells.  11  antibodies  recognized polymorphic 
determinants  in  the  mouse,  and,  by using  target  cells  from  MHC  congenic  mouse 
strains,  it  was shown that  these  determinants  are  encoded by genes within  the  H-2 
complex.  Finally,  by considering the overall reactivity patterns  of these monoclonal 
antibodies  on  all  target  cells,  one  can  show  that  these  24  antibodies  represent  a 
minimum of 14 antibody specificities. 
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